Close Menu

NanoString

NEW YORK (GenomeWeb) – NanoString Technologies continues to benefit from sales to clinical laboratories.

Qiagen said this week that Detlev Riesner, a Qiagen co-founder, retired earlier this month as chairman of the company's supervisory board after having served as a member of the board since 1996 and as chairman since 2003.

NEW YORK (GenomeWeb) – NanoString Technologies reported after the close of the market Wednesday that its first quarter revenues increased 54 percent year over year as its instrument sales doubled.

NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that Canadian regulatory authorities have cleared the firm's Prosigna Breast Cancer Prognostic Gene Signature Assay for marketing.

NEW YORK (GenomeWeb) – Veracyte, Rosetta Genomics, and NanoString Technologies led a lineup of firms in the GenomeWeb Daily News Index that saw their share prices retreat in April, as the Index took a 5 percent hit during the month.

NanoString Technologies this week launched its nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that enables translational researchers to investigate cancer biology across all major cancer pathways.

NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market on Thursday it has reached a term loan agreement with Capital Royalty and certain of its affiliates to borrow up to $45 million.

Weakness in the broader biotech space dragged down the shares of companies in the life sciences tools and molecular diagnostics spaces in March, as 21 of the 29 firms in the GenomeWeb Daily News Index saw their stocks decline during the month.

With new publications and an expanding sales force, NanoString is ramping up its efforts to bolster adoption of its Prosigna breast cancer recurrence test.

NanoString Technologies' increasingly diverse portfolio of molecular analysis products is set to expand in coming quarters.

Pages

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.